These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 26033545)

  • 21. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
    Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
    Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
    J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-grade and anaplastic oligodendroglioma.
    Van Den Bent MJ; Bromberg JE; Buckner J
    Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion.
    Kanazawa T; Minami Y; Takahashi H; Fujiwara H; Toda M; Jinzaki M; Yoshida K; Sasaki H
    Neurosurg Rev; 2020 Aug; 43(4):1211-1219. PubMed ID: 31402410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
    Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
    World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
    Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
    Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
    Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
    J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
    Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
    Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
    Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI and CT Identify Isocitrate Dehydrogenase
    Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
    Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.
    Castet F; Alanya E; Vidal N; Izquierdo C; Mesia C; Ducray F; Gil-Gil M; Bruna J
    J Neurooncol; 2019 Jul; 143(3):515-523. PubMed ID: 31054099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.